Logo del repository
  1. Home
 
Opzioni

Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis.

Fargnoli MC
•
Esposito M
•
Ferrucci S
altro
Dupilumab Italian National Access Program (Dup-INAP group).
2021
  • journal article

Periodico
JOURNAL OF DERMATOLOGICAL TREATMENT
Abstract
Background: Dupilumab, a fully human monoclonal antibody targeting the alpha subunit of IL-4 was recently approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients. Objective: To assess dupilumab effectiveness and safety in adults with moderate-to-severe AD in a real-life Italian multicentre retrospective cohort. Methods: Adult moderate-to-severe AD patients, referring to 39 Italian centres, received dupilumab in the context of a national patient access program. Disease assessment was performed at baseline, after 4 and 16 weeks of treatment using Eczema-Area-and-Severity-Index (EASI) score, itch and sleep numerical-rating-score (itch-NRS, sleep-NRS) and Dermatology-Life-Quality-Index (DLQI). Results: A total of 109 (71M/38F) patients was studied. There was a significant reduction in EASI score, itch-NRS, sleep-NRS and DLQI from baseline to week 4 and a further significant decline to week 16. EASI 50, EASI75 and EASI90 were achieved by 59.6%, 28.4% and 9.3% of patients at 4 weeks and by 87.2%, 60.6% and 32.4% of them at 16 weeks, respectively. Adverse events were experienced by 19.2% (21/109) of the patients and they were all mild in intensity, being conjunctivitis the most common side effect. Conclusions: Dupilumab significantly improved disease severity, pruritus, sleep loss and quality of life with an acceptable safety profile.
DOI
10.1080/09546634.2019.1682503
WOS
WOS:000492806000001
Archivio
http://hdl.handle.net/11368/2952077
info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85074489880
https://www.tandfonline.com/doi/abs/10.1080/09546634.2019.1682503?journalCode=ijdt20
Diritti
open access
license:copyright editore
license:copyright editore
FVG url
https://arts.units.it/request-item?handle=11368/2952077
Soggetti
  • atopic dermatiti

  • dupilumab

  • real-life

Scopus© citazioni
23
La settimana scorsa
1
Data di acquisizione
Jun 14, 2022
Vedi dettagli
Web of Science© citazioni
64
Data di acquisizione
Mar 23, 2024
Visualizzazioni
8
Data di acquisizione
Apr 19, 2024
Vedi dettagli
google-scholar
Get Involved!
  • Source Code
  • Documentation
  • Slack Channel
Make it your own

DSpace-CRIS can be extensively configured to meet your needs. Decide which information need to be collected and available with fine-grained security. Start updating the theme to match your nstitution's web identity.

Need professional help?

The original creators of DSpace-CRIS at 4Science can take your project to the next level, get in touch!

Realizzato con Software DSpace-CRIS - Estensione mantenuta e ottimizzata da 4Science

  • Impostazioni dei cookie
  • Informativa sulla privacy
  • Accordo con l'utente finale
  • Invia il tuo Feedback